The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.

Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.

Fibromyalgia is a highly prevalent disorder with different studies and populations showing a prevalence of 2.1% to 6.4% in the general population.  A retrospective review from Olmstead county revealed that among 1

Patients rate communication as one of the most important factors in choosing and sticking with a physician. The end product in at least 2/3 of visits is the prescription, yet prescription adherence is substandard in half of our patients. The key is communication.

In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.

An advisory board has recommended osteoarthritis and a host of disorders for inclusion in the Illinois new medical marijuana program.

In the last 12 months, levothyroxine (Synthroid) was the most prescribed drug in the USA  with 21.6 million prescriptions. Adalimumab (Humira) had 8.3 billion in sales, followed by etanercept (Enbrel) at nearly $6 billion. 

Unused pills and prescriptions pose a significant safety risk in the home and may contribute to dosing errors or inadvertent drug use. The issue has led the DEA to sponsor national drug disposal programs and local municipalities have followed with similar programs. At issue is who shoul

A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.

Medicare released its list of the most costly medicines presribed in 2013.

The generic drug manufactuer Actavis joins Teva and Mylan with their lauch of celecoxib (Celebrex)in 50 mg, 100 mg, 200 mg and 400 mg capsules. In 2013 celecoxib was the 21st leading prescribed drug in the U.S. with $2.4 billion in sales as of mid 2014.

Congress investigates why the price of more than 1,200 generic medications increased an average 448% betweeen 2013-2014.http://buff.ly/1v56VUt

The patients out of pocket costs for  "Specialty Drugs" will increase significantly in 2015.